Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

M's Science Corp.

www.m-sci.com

Latest From M's Science Corp.

Venturing into the Japanese investment market with Mebiopharm

In many ways, Mebiopharm's investment experience is illustrative of the challenges facing the bioventure sector as a whole in Japan, or indeed anywhere else. The need to secure sufficient funding and maintain momentum for lead pipeline projects will no doubt sound familiar to the management of any startup looking to commercialize new technology.

Cancer Neurology

Schizophrenia Dominates Psychiatric Drug Deal-Making Since 2008

Of 34 deals in the psychiatric disorder space since 2008, none have been mergers and acquisitions, but two-thirds of such transactions have involved licensing of compounds before regulatory approval. The major deals in the space have been a multi-compound collaboration between Otsuka and Lundbeck and the failed tie-up between AstraZeneca and Targacept.

BioPharmaceutical North America

Mind over matter - partnerships: CNS deals signed over the past five years

Attention deficit hyperactivity disorder (ADHD)

Date

 

Company

 

Partner

 

Deal terms

 

March 2009

 

GlaxoSmithKline

 

Shire

 

co-promotion of Shire's Vyvanse (lisdexamfetamine dimesylate) for the treatment of attention deficit hyperactivity disorder in the US

 

November 2008

 

GlaxoSmithKline

 

Paladin Labs

 

three-year contract giving Paladin exclusive distribution rights for GSK's Dexedrine (dextroamphetamine sulfate) for the treatment of ADHD and in the adjunctive treatment of narcolepsy, in Canada

 

Neurology Mexico
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • M's Science Corp.
  • Senior Management
  • Shiro Mita, PhD, Chmn. & CEO
    Takeshi Maeda, CFO
  • Contact Info
  • M's Science Corp.
    Phone: (81) 78-200-5063
    5-1-14, Hamabe-dori
    Kobe , 651-0083
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register